3182
J.-I. K. Almstead et al. / Tetrahedron: Asymmetry 9 (1998) 3179–3183
There are several methods reported in the literature for introduction of α,β-unsaturation into cyclic
13
ketones. We were interested in a versatile yet direct conversion of 15 to either an α,β-unsaturated
aldehyde or an ester. This was achieved by a two-step process which successfully utilized a palladium-
catalyzed reaction. The ketone 15a was treated with LDA, and the resulting enolate was trapped in situ
with N-phenyl triflamide to provide the enol triflate 16 in 60% yield (Scheme 5). In order to ensure
complete enolate formation alpha to a neopentyl center, the reaction mixture was allowed to warm
to room temperature. Reaction of the enol triflate with a catalytic amount of tetrakis(triphenylphos-
phine)palladium and carbon monoxide in the presence of either methanol or n-Bu SnH provided the
3
CO insertion products, 17 or 18, respectively (55 or 67% yield). Following the removal of the silyl
protecting group from 18 with p-toluenesulfonic acid, the resulting alcohol was oxidized with pyridinium
chlorochormate to provide the target dialdehyde 1 in 90% yield.
Scheme 5.
The diastereoselective coupling of the dialdehyde with a clerocidin-like side chain can be achieved
through a chromium-mediated reaction which has been employed successfully with other systems.14 The
design, synthesis, and scope of the optically active side chain precursor of clerocidin will be described in
a separate communication.
In summary, the diterpene backbone was efficiently constructed using an asymmetric Robinson
annulation method. Two key reactions made the synthesis of optically active 1 feasible: first, the
stereoselective hydrogenation of the exocyclic double bond in 13 provided the less stable product
which was crucial to achieving trans C –C dimethyl stereochemistry and, second, the α,β-unsaturated
8
9
aldehyde 18 was prepared in two steps via the enol triflate 16 and palladium chemistry.
References
1. (a) Andersen, N. R.; Lorck, H. O. B; Rasmussen, P. R. J. Antibiotics 1983, 753. (b) McCullough, J. E.; Muller, M. T.;
Howells, A. J.; Maxwell, A.; O’Sullivan, J.; Summerill, R. S.; Parker, W. L.; Wells, J. S.; Bonner, D. P. J. Antibiotics 1993,
235.
2
3
. (a) Andersen, N. R.; Rasmussen, P. R. Tetrahedron Lett. 1984, 25(4) 465. (b) Ibid, Tetrahedron Lett. 1984, 25(4), 469.
. (a) Tamamura, T.; Sawa, T.; Isshiki, K.; Masuda, T.; Homma, Y.; Iinuma, H.; Naganawa, H.; Hamada, M.; Takeuchi, T.;
Umezawa, H. J. Antibiotics 1985, 1664. (b) Tamamura, T.; Tsuchiya, M.; Isshiki, K.; Sawa, T.; Takeuchi, T. J. Antibiotics
1988, 648. (c) Kawada, S.; Yamashita, Y.; Uosaki, Y.; Gomi, K.; Iwasaki, T.; Takiguchi, T.; Nakano, H. J. Antibiotics 1992,
1182.
4
. (a) (−)-Kolavenol and (−)-agelasine B: Piers, E.; Roberge, J. Y. Tetrahedron Lett. 1991, 32(39), 5219. (b) Ibid, Tetrahedron
Lett. 1992, 33(46), 6923. (c) trans-Maingayic acid: Tokoroyama, T.; Fujimori, K.; Shimizu, T.; Yamagiwa, Y.; Monden,
M.; Iio, H. Tetrahedron 1988, 44(21), 6607. (d) rac-Avarol: Sarma, A. S.; Chattopadhyay, P. J. Org. Chem. 1982, 47, 1727.
(e) rac-Annonene: Takahashi, S.; Kusumi, S.; Kakisawa, H. Chem. Lett. 1979, 515.
5. (a) rac-epi-Ajugarin I and rac-ajugarin I: Luteijn, J. M.; de Groot, A. Tetrahedron Lett. 1982, 3421. (b) rac-Ajugarin I:
Ley, S. V.; Simpkins, N. S.; Whittle, A. J. J. Chem. Soc., Chem. Commun. 1983, 503. (c) Ibid, Tetrahedron 1986, 42(23),
6519. (d) rac-Ajugarin IV: Kende, A. S.; Roth, B.; Kubo, I. Tetrahedron Lett. 1982, 1751.